LHRH analogues in breast cancer: clever, but do we need them?
1991
LHRH Analogues in Breast Cancer: Do We Need Them?
Sample size: 75
Editorial
Evidence: moderate
Author Information
Author(s): I.E. Smith
Primary Institution: Royal Marsden Hospital
Conclusion
LHRH analogues are effective in treating metastatic breast cancer, but their necessity compared to other treatments like tamoxifen is questionable.
Supporting Evidence
- LHRH analogues can suppress plasma oestrogens within 2-3 weeks.
- 33% of premenopausal patients treated with goserelin achieved an objective tumour response.
- Tamoxifen is as effective as oophorectomy with minimal toxicity.
Takeaway
LHRH analogues can help treat breast cancer, but there are other options that might be just as good or better.
Methodology
The article discusses the use of LHRH analogues in breast cancer treatment, referencing various studies and clinical trials.
Limitations
The clinical effects of LHRH analogues in postmenopausal women appear to be small and probably unimportant compared to other therapies.
Participant Demographics
The study involved premenopausal women with metastatic breast cancer.
Want to read the original?
Access the complete publication on the publisher's website